Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells

Bagca B. , Ozates N. P. , AŞIK A. , Caglar H. O. , GÜNDÜZ C. , Avci C. B.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, cilt.533, ss.1497-1504, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 533 Konu: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.bbrc.2020.10.058
  • Sayfa Sayıları: ss.1497-1504


Temozolomide (TMZ) is used in the standard therapy regimen for patients with glioblastoma (GBM). However, some GBM patients do not respond to TMZ therapy. The combining therapeutic agents in GBM treatment are attracting considerable interest due to TMZ resistance. This study aims to identify the combinatorial effect of TMZ and AZD3463 on the viability of the T98G GBM cells. The cytotoxic effects of compounds were determined by using WST-8 assay. Flow cytometry was used to determine apoptosis and cell cycle profiles after treatments. Real-time PCR was used to identify mRNA expression of genes in the PI3K/AKT signaling pathway after treatments. IC50 concentrations of TMZ and AZD3463 were found to be 1.54 mM and 529 nM after incubation for 48 h, respectively. The combination treatment showed a synergistic effect on reducing the viability of GBM cells. Each one of TMZ, AZD3463, and combination treatments induced apoptosis. Treatments, either alone or the combination of these agents, caused the cell cycle arrest in distinct phases. TMZ and AZD3463 treatments, either alone or in combination, downregulated mRNA expression of genes in the PI3K/AKT signaling pathway. The combination of TMZ with AZD3463 may increase the efficacy of single TMZ treatment in GBM cells due to decreased expression of genes in the PI3K/AKT signaling pathway that is responsible for drug resistance and intratumoral heterogeneity. (C) 2020 Elsevier Inc. All rights reserved.